Io Therapeutics, Inc., presented data from studies of IRX4204, the company’s phase II clinical development stage, highly selective third generation RXR nuclear receptor agonist compound, supporting its potential use for prevention and treatment of normal 10-07-2024, 07:00

Stirling CBD Forecasts CBD Use to Grow in 2023 23-02-2023, 01:03

Rezolve AI Limited Closes Business Combination with Armada Acquisition Corp. I; Announces Date for Commencement of Trading on the Nasdaq; Launching one of the first pure play Ai companies with its own foundation Large Language Model - brainpowa 16-08-2024, 04:27